2024-02-012025-01-312025-01-31false14606775CAPSARIS PHARMA LTD2025-10-30falseiso4217:GBPxbrli:pure146067752024-01-31146067752025-01-31146067752024-02-012025-01-31146067752023-01-19146067752024-01-31146067752023-01-202024-01-3114606775bus:SmallEntities2024-02-012025-01-3114606775bus:AuditExempt-NoAccountantsReport2024-02-012025-01-3114606775bus:FullAccounts2024-02-012025-01-3114606775bus:PrivateLimitedCompanyLtd2024-02-012025-01-3114606775core:WithinOneYear2025-01-3114606775core:AfterOneYear2025-01-3114606775core:WithinOneYear2024-01-3114606775core:AfterOneYear2024-01-3114606775core:ShareCapital2025-01-3114606775core:SharePremium2025-01-3114606775core:RevaluationReserve2025-01-3114606775core:OtherReservesSubtotal2025-01-3114606775core:RetainedEarningsAccumulatedLosses2025-01-3114606775core:ShareCapital2024-01-3114606775core:SharePremium2024-01-3114606775core:RevaluationReserve2024-01-3114606775core:OtherReservesSubtotal2024-01-3114606775core:RetainedEarningsAccumulatedLosses2024-01-3114606775core:LandBuildings2025-01-3114606775core:PlantMachinery2025-01-3114606775core:Vehicles2025-01-3114606775core:FurnitureFittings2025-01-3114606775core:OfficeEquipment2025-01-3114606775core:NetGoodwill2025-01-3114606775core:IntangibleAssetsOtherThanGoodwill2025-01-3114606775core:ListedExchangeTraded2025-01-3114606775core:UnlistedNon-exchangeTraded2025-01-3114606775core:LandBuildings2024-01-3114606775core:PlantMachinery2024-01-3114606775core:Vehicles2024-01-3114606775core:FurnitureFittings2024-01-3114606775core:OfficeEquipment2024-01-3114606775core:NetGoodwill2024-01-3114606775core:IntangibleAssetsOtherThanGoodwill2024-01-3114606775core:ListedExchangeTraded2024-01-3114606775core:UnlistedNon-exchangeTraded2024-01-3114606775core:LandBuildings2024-02-012025-01-3114606775core:PlantMachinery2024-02-012025-01-3114606775core:Vehicles2024-02-012025-01-3114606775core:FurnitureFittings2024-02-012025-01-3114606775core:OfficeEquipment2024-02-012025-01-3114606775core:NetGoodwill2024-02-012025-01-3114606775core:IntangibleAssetsOtherThanGoodwill2024-02-012025-01-3114606775core:ListedExchangeTraded2024-02-012025-01-3114606775core:UnlistedNon-exchangeTraded2024-02-012025-01-3114606775core:MoreThanFiveYears2024-02-012025-01-3114606775core:Non-currentFinancialInstruments2025-01-3114606775core:Non-currentFinancialInstruments2024-01-3114606775dpl:CostSales2024-02-012025-01-3114606775dpl:DistributionCosts2024-02-012025-01-3114606775core:LandBuildings2024-02-012025-01-3114606775core:PlantMachinery2024-02-012025-01-3114606775core:Vehicles2024-02-012025-01-3114606775core:FurnitureFittings2024-02-012025-01-3114606775core:OfficeEquipment2024-02-012025-01-3114606775dpl:AdministrativeExpenses2024-02-012025-01-3114606775core:NetGoodwill2024-02-012025-01-3114606775core:IntangibleAssetsOtherThanGoodwill2024-02-012025-01-3114606775dpl:GroupUndertakings2024-02-012025-01-3114606775dpl:ParticipatingInterests2024-02-012025-01-3114606775dpl:GroupUndertakingscore:ListedExchangeTraded2024-02-012025-01-3114606775core:ListedExchangeTraded2024-02-012025-01-3114606775dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-02-012025-01-3114606775core:UnlistedNon-exchangeTraded2024-02-012025-01-3114606775dpl:CostSales2023-01-202024-01-3114606775dpl:DistributionCosts2023-01-202024-01-3114606775core:LandBuildings2023-01-202024-01-3114606775core:PlantMachinery2023-01-202024-01-3114606775core:Vehicles2023-01-202024-01-3114606775core:FurnitureFittings2023-01-202024-01-3114606775core:OfficeEquipment2023-01-202024-01-3114606775dpl:AdministrativeExpenses2023-01-202024-01-3114606775core:NetGoodwill2023-01-202024-01-3114606775core:IntangibleAssetsOtherThanGoodwill2023-01-202024-01-3114606775dpl:GroupUndertakings2023-01-202024-01-3114606775dpl:ParticipatingInterests2023-01-202024-01-3114606775dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-202024-01-3114606775core:ListedExchangeTraded2023-01-202024-01-3114606775dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-202024-01-3114606775core:UnlistedNon-exchangeTraded2023-01-202024-01-3114606775core:NetGoodwill2025-01-3114606775core:IntangibleAssetsOtherThanGoodwill2025-01-3114606775core:LandBuildings2025-01-3114606775core:PlantMachinery2025-01-3114606775core:Vehicles2025-01-3114606775core:FurnitureFittings2025-01-3114606775core:OfficeEquipment2025-01-3114606775core:AfterOneYear2025-01-3114606775core:WithinOneYear2025-01-3114606775core:ListedExchangeTraded2025-01-3114606775core:UnlistedNon-exchangeTraded2025-01-3114606775core:ShareCapital2025-01-3114606775core:SharePremium2025-01-3114606775core:RevaluationReserve2025-01-3114606775core:OtherReservesSubtotal2025-01-3114606775core:RetainedEarningsAccumulatedLosses2025-01-3114606775core:NetGoodwill2024-01-3114606775core:IntangibleAssetsOtherThanGoodwill2024-01-3114606775core:LandBuildings2024-01-3114606775core:PlantMachinery2024-01-3114606775core:Vehicles2024-01-3114606775core:FurnitureFittings2024-01-3114606775core:OfficeEquipment2024-01-3114606775core:AfterOneYear2024-01-3114606775core:WithinOneYear2024-01-3114606775core:ListedExchangeTraded2024-01-3114606775core:UnlistedNon-exchangeTraded2024-01-3114606775core:ShareCapital2024-01-3114606775core:SharePremium2024-01-3114606775core:RevaluationReserve2024-01-3114606775core:OtherReservesSubtotal2024-01-3114606775core:RetainedEarningsAccumulatedLosses2024-01-3114606775core:NetGoodwill2023-01-1914606775core:IntangibleAssetsOtherThanGoodwill2023-01-1914606775core:LandBuildings2023-01-1914606775core:PlantMachinery2023-01-1914606775core:Vehicles2023-01-1914606775core:FurnitureFittings2023-01-1914606775core:OfficeEquipment2023-01-1914606775core:AfterOneYear2023-01-1914606775core:WithinOneYear2023-01-1914606775core:ListedExchangeTraded2023-01-1914606775core:UnlistedNon-exchangeTraded2023-01-1914606775core:ShareCapital2023-01-1914606775core:SharePremium2023-01-1914606775core:RevaluationReserve2023-01-1914606775core:OtherReservesSubtotal2023-01-1914606775core:RetainedEarningsAccumulatedLosses2023-01-1914606775core:AfterOneYear2024-02-012025-01-3114606775core:WithinOneYear2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:CostValuation2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3114606775core:Non-currentFinancialInstrumentscore:CostValuation2025-01-3114606775core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-3114606775core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-3114606775core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-3114606775core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-3114606775core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-3114606775core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-3114606775core:Non-currentFinancialInstrumentscore:CostValuation2024-01-3114606775core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-3114606775bus:Director12024-02-012025-01-3114606775bus:Director22024-02-012025-01-3114606775bus:Director32024-02-012025-01-3114606775bus:Director42024-02-012025-01-31

CAPSARIS PHARMA LTD

Registered Number
14606775
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2025

CAPSARIS PHARMA LTD
Company Information
for the year from 1 February 2024 to 31 January 2025

Directors

ANYAMENE, Ifesinachi Chidinma
ANYAMENE, Okechukwu Joseph
NZE, Ebele
NZE, Ikenna Uzodimma

Registered Address

64 Windham Avenue New Addington
Croydon
CR0 0HW

Registered Number

14606775 (England and Wales)
CAPSARIS PHARMA LTD
Balance Sheet as at
31 January 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets3298,600334,078
Tangible assets411,32911,224
309,929345,302
Current assets
Stocks537,75045,601
Debtors6101,729112,581
Cash at bank and on hand79,58667,547
219,065225,729
Creditors amounts falling due within one year7(528,231)(558,799)
Net current assets (liabilities)(309,166)(333,070)
Total assets less current liabilities76312,232
Net assets76312,232
Capital and reserves
Called up share capital100100
Profit and loss account66312,132
Shareholders' funds76312,232
The financial statements were approved and authorised for issue by the Board of Directors on 30 October 2025, and are signed on its behalf by:
NZE, Ikenna Uzodimma
Director
Registered Company No. 14606775
CAPSARIS PHARMA LTD
Notes to the Financial Statements
for the year ended 31 January 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Goodwill
Goodwill arising on an acquisition of a business is carried at cost less accumulated impairment losses, if any. Goodwill is amortised over its expected useful life which is estimated to be ten years. Goodwill is assessed for impairment when there are indicators of impairment and any impairment is charged to the income statement. No reversals of impairment are recognised.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)Straight line (years)
Plant and machinery15-
Office Equipment-3
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20252024
Average number of employees during the year53
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 February 24354,773354,773
At 31 January 25354,773354,773
Amortisation and impairment
At 01 February 2420,69520,695
Charge for year35,47835,478
At 31 January 2556,17356,173
Net book value
At 31 January 25298,600298,600
At 31 January 24334,078334,078
4.Tangible fixed assets

Plant & machinery

Office Equipment

Total

£££
Cost or valuation
At 01 February 2412,300-12,300
Additions-1,8401,840
At 31 January 2512,3001,84014,140
Depreciation and impairment
At 01 February 241,076-1,076
Charge for year1,684511,735
At 31 January 252,760512,811
Net book value
At 31 January 259,5401,78911,329
At 31 January 2411,224-11,224
5.Stocks

2025

2024

££
Finished goods37,75045,601
Total37,75045,601
6.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables80,72985,563
Other debtors21,00027,018
Total101,729112,581
7.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables80,13771,523
Amounts owed to related parties397,446431,787
Taxation and social security9,2056,345
Payments received on account31,53840,854
Other creditors6,557-
Accrued liabilities and deferred income3,3488,290
Total528,231558,799
8.Related party transactions
At the yearend, the company owed £205,378 (2024: 222,378) and £192,068 (2024: £209,409) to Capsaris Holdings Limited and Capsaris (UK) Limited respectively. The companies are related as Mr. I U Nze, Mr. O J Anyamene, Mrs. I C Anyamene and Mrs E NZE are also the directors of these companies.